merged_china-pharma-drugs.txt
<question_number>1</question_number>
<answer>N/A</answer>
<question_number>2</question_number>
<answer>N/A</answer>
<question_number>3</question_number>
<answer>N/A</answer>
<question_number>4</question_number>
<answer>N/A</answer>
<question_number>5</question_number>
<answer>N/A</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>The proposal suggested allowing patients to get an original branded drug even if it was not on the approved procurement list, with insurance reimbursement adjusted depending on whether the drug was from an original branded drug or a generic.</answer>
<question_number>8</question_number>
<answer>N/A</answer>
<question_number>9</question_number>
<answer>N/A</answer>
<question_number>10</question_number>
<answer>N/A</answer>
<question_number>11</question_number>
<answer>China's National Healthcare Security Administration</answer>
<question_number>12</question_number>
<answer>Xia Zhimin</answer>
<question_number>13</question_number>
<answer>Zheng Minhua, the director of surgery at Ruijin Hospital in Shanghai</answer>
<question_number>14</question_number>
<answer>The volume-based procurement system</answer>
<question_number>15</question_number>
<answer>A former editor at a leading online health platform</answer>
<question_number>16</question_number>
<answer>The policy that encourages fierce competition between drug manufacturers and was put in place in 2018</answer>
<question_number>17</answer>
<answer>Lu Changlin</answer>
<question_number>18</question_number>
<answer>China's government</answer>
<question_number>19</question_number>
<answer>Private clinics</answer>
<question_number>20</question_number>
<answer>Xia Zhimin</answer>